This study shows how AI can change the way drugs are made and delivered, making healthcare faster, more personalized, and cheaper.

This study demonstrates interpretable, robust modeling for Parkinson’s telemonitoring, guiding reliable disease progression prediction under small-sample longitudinal data constraints.

Clarifies the potential role of vitamin D and kidney dysfunction in diabetic nephropathy through clinical and molecular analysis.

The results demonstrate a strong link between vitamin D deficiency and an increased risk of coronary heart disease in adults.

AI-driven contrast mapping enhances voxel-level T2-MRI brain analysis, revealing phenotypic variations crucial for early diagnosis and neurodevelopmental profiling 

This review elucidates autoimmune mechanisms in Crohn’s disease, highlighting emerging molecular targets to advance precision immunotherapy and improve patient outcomes.

Integrating predictive analytics, reinforcement learning, and causal inference improves maternal outcomes by aligning risk prediction with real-time, equity-aware resource allocation decisions.

This study provides preliminary clinical evidence that standardized Orthosiphon stamineus extract may meaningfully reduce serum uric acid in hyperuricemic adults.

Bridges experimental and computational toxicology to enable predictive, human-relevant risk assessment frameworks for safer and faster chemical evaluation

This study integrates biomedical and ecological research, revealing shared biological mechanisms that inform therapeutic innovation, sustainable agriculture, and systems-level understanding of complex biological interactions.

This study demonstrates that dietary bioactive compounds play a significant role in reducing the risk of chronic diseases, improving cardiovascular health, and offering protective effects against certain types of cancer.

Multimodal, precision-guided angiogenic therapies—gene, cell, extracellular vesicle, and biomaterial-based—offer transformative potential for treating ischemic diseases where revascularization remains unfeasible.

Epigenetic clocks convert DNA methylation into a modifiable biomarker, repositioning ageing as a treatable clinical target.

Spatial multi-omics repositions tissue context as a first-class clinical variable, but equitable, standardized translation remains unfinished business.

This study highlights how prenatal endocrine disruptor exposure impairs neurodevelopment, emphasizing mixture effects, biological mechanisms, and urgent regulatory intervention needs.

Spatial transcriptomics reveals disease architecture at cellular resolution, but cost, FFPE limits, and complexity keep it from routine clinical diagnostics.

This review reframes chronic neurodegenerative and autoimmune disease through a reproducible, microbiome-centered mechanistic and therapeutic lens.

Explains why highly accurate AI resistance models fail clinically, and outlines concrete validation, equity, and deployment fixes.

Mapping senescent-cell heterogeneity to precision senotherapies could transform multimorbid, age-related disease treatment safely

AI compresses AMR diagnosis and discovery timelines dramatically, yet no tool has reached regulatory clearance — validation and trust, not algorithms, remain the bottleneck.

Extracellular vesicles promise cell-free precision diagnostics and therapeutics, but standardization, scalability, and regulatory gaps still block routine clinical adoption.

Bariatric-level pharmacotherapy now exists, yet muscle loss, rebound, cost, and pediatric uncertainty still limit its real-world promise.

Organoid-on-chip systems merge biological fidelity with engineering precision, offering AI-augmented, human-relevant platforms positioned to reshape preclinical drug development.

Intercellular mitochondrial transfer sustains tissue bioenergetics and immunity, offering a transformative, biologically grounded therapeutic strategy for degenerative and ischemic disease.

Tissue-resident memory T cells permanently guard peripheral organs, but their dysregulation drives chronic autoimmune disease, making them a precise emerging therapeutic target.

Frailty-based, mechanism-anchored prescribing frameworks could replace single-disease guidelines that quietly harm complex older patients.

Reframing Long COVID as a biologically stratifiable network disorder could finally make targeted, effective treatment trials possible.

AMR is outpacing critical-care antibiotics; precision genomic, antibody, peptide, and nanozyme strategies may restore therapeutic options.

Integrating transcriptomic, epigenetic, and functional organoid data with genomics may finally close oncology’s persistent gap between diagnosis and matched treatment.

Wearable digital biomarkers show strong clinical validity but require standardized validation, interoperable data systems, and equitable design before routine adoption.

Artificial-intelligence risk models and digital twins could shift cardiology from reactive treatment toward proactive, individualized prevention — if bias, validation, and trust gaps are honestly addressed.

Environmental exposures converge with genetic risk to trigger autoimmune flares, guiding precision prevention beyond genetics alone.

Non-coding RNA networks orchestrate pancreatic cancer progression, immune evasion, and chemoresistance, revealing druggable nodes for precision therapy.

Mapping how ALS/FTD proteins phase-separate and solidify reveals shared biophysical vulnerabilities that could be therapeutically exploited across the disease spectrum.

Epigenome editing may silence sickle-globin defects without DNA cleavage, offering a safer, durable alternative to nuclease-based gene therapy.

Protein language models can resolve uncertain BRCA variants rapidly, potentially widening equitable access to PARP-inhibitor therapy worldwide.

RNA modifications reprogram liver-cancer transcripts to drive growth, immune escape, and drug resistance—offering new biomarkers and druggable targets.

STAG2/cohesin loss and oncofusion proteins collapse 3D chromatin loops in AML, silencing differentiation genes while revealing druggable, reversible epigenetic vulnerabilities.

Cellular senescence organizes IPF pathogenesis across cell types, positioning senotherapeutics and regenerative cell therapy as biologically grounded strategies for reversing, not merely slowing, fibrosis.

This study clarifies structural features driving potent α-glycosidase inhibition, enabling rational design of selective therapeutics through integrated computational–experimental mechanistic insights.